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The prevalence of neutralizing antibody against West 
Caucasian bat virus (WCBV) in Miniopterus bats collected 
in Kenya ranged from 17% to 26%. Seropositive bats were 
detected in 4 of 5 locations sampled across the country. 
These ﬁ  ndings provide evidence that WCBV, originally iso-
lated in Europe, may emerge in other continents.
B
ats are reservoir hosts of several emerging zoonotic 
RNA viruses (1). In particular, bats host a range of 
lyssaviruses, as has been reported from different continents 
(2). Presently, 7 species are recognized within the genus 
Lyssavirus (order Mononegavirales, family Rhabdoviri-
dae): Rabies virus (RABV), Lagos bat virus (LBV), Moko-
la virus (MOKV), Duvenhage virus (DUVV), European 
bat lyssavirus, types 1 and 2, and Australian bat lyssavirus. 
Another 4 lyssaviruses, all isolated from bats, have been 
assigned to the genus as putative species: Aravan virus, 
Khujand virus, Irkut virus, and West Caucasian bat virus 
(WCBV) (3).
RABV infection of bats is known in the Americas, but 
not in the Old World. Four lyssavirus species have been 
documented in Africa. Of these, RABV and MOKV have 
been isolated exclusively from terrestrial mammals, where-
as LBV and DUVV are associated with bats and have been 
isolated only occasionally from other mammals (4). On the 
basis of this diversity and on the serologic cross-reactivity 
of MOKV with African non-lyssa rhabdoviruses, it has 
been hypothesized that Africa is the continent of the origin 
and initial evolution of members of the genus Lyssavirus 
(5). However, this hypothesis has been called into question 
by the isolation of WCBV in southeastern Europe. WCBV 
is the most divergent member of the genus Lyssavirus to 
date and has long genetic distances and lack of serologic 
cross-reactivity to other lyssaviruses (6,7). Our study ob-
jective was to enhance pathogen discovery for zoonotic 
agents in African bats, with particular focus on lyssavirus 
surveillance in Kenya.
The Study
During 2006–2007, bats of at least 30 species were 
collected from 25 locations in Kenya (Figure 1, panel A; 
online Appendix Table, available from www.cdc.gov/EID/
content/14/12/1887-appT.htm). The sample numbers and 
collection protocol were approved by the National Museum 
of Kenya and the Kenya Wildlife Service. Of the 1,221 bats 
collected, only 12 were sick or dead; the others appeared 
healthy. Captured animals were anesthetized by an intra-
muscular injection of ketamine hydrochloride (0.05–0.1 
mg/g) and euthanized under sedation in compliance with 
a ﬁ  eld protocol approved by the Animal Institute Care and 
Use Committee of the Centers for Disease Control and Pre-
vention. Bat size, sex, and species were identiﬁ  ed. When 
phenotypic species determination was not possible, DNA 
specimens were submitted for identiﬁ  cation to the Univer-
sity of Guelph (Ontario, Canada), where partial sequences 
of the cytochrome oxidase gene were generated and com-
pared with those available from the Barcode of Life Data 
Systems (www.boldsystems.org).
The brain and other organs of bats were collected into 
sterile plastic tubes. Oral swabs were collected and placed 
in tubes containing Minimum Essential Medium (MEM-
10, Invitrogen, Grand Island, NY, USA) for virus isolation 
or in TRIzol (Invitrogen, Carlsbad, CA, USA) for RNA ex-
traction. Serum was separated from the blood clot by cen-
trifugation. All samples were transported on dry ice and 
stored at –80oC.
The brains (n = 1,182) were subjected to the direct 
ﬂ  uorescent antibody test for lyssavirus antigen (8). In ad-
dition, the 277 brains that were collected in 2006 were ho-
mogenized and tested for virus isolation by the intracerebral 
mouse inoculation test as described elsewhere (9). Virus 
isolation was attempted for only a subset of brain samples 
(n = 210) from the specimens collected during 2007.
Total RNA was extracted from the oral swabs (n = 
931) and subjected to nested reverse transcription–PCR, as 
described previously (10). We used primers designed for 
the nucleoprotein genes of LBV, MOKV, and WCBV.
The virus neutralizing antibodies in bat serum samples 
were determined by a modiﬁ  cation of the rapid ﬂ  uores-
cent focus inhibition test. We used 4-well (6-mm) Teﬂ  on-
coated glass slides (Cel-Line, Erie Scientiﬁ  c, Portsmouth, 
NH, USA) as described elsewhere (10). Previous tests for 
RABV neutralizing antibodies have demonstrated that re-
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classical test in chamber slides. The neutralizing activity of 
each serum sample was determined against LBV, MOKV, 
DUVV, RABV, and WCBV. All samples were initially 
screened in dilutions of 1:10 and 1:25. Samples that showed 
reduced ﬂ  uorescence or no ﬂ  uorescence were subjected to 
additional titration in dilutions of 1:10 to 1:1,250. The 50% 
end-point neutralizing titers were calculated by the method 
of Reed and Muench (11). The samples that had a 50% end-
point neutralizing titer >1 log10 were considered positive.
Circulation of LBV was detected in fruit bats Eidolon 
helvum and Rousettus aegyptiacus as described previously 
(10). No other viruses were isolated during the study, and 
no lyssavirus RNA was identiﬁ  ed in oral swabs. However, 
virus-neutralizing activity against WCBV was detected in 
serum of Miniopterus insectivorous bats (Figure 2) from 
4 of the 5 locations where these species were collected 
(online Appendix Table). Among 76 serum samples with 
WCBV-neutralizing activity (Figure 1, panel B), only 1 
sample additionally neutralized DUVV, but no cross-neu-
tralization to other lyssaviruses was detected. This obser-
vation supported speciﬁ  city of the reaction and reliability 
of the selected cutoff threshold. The seroprevalence varied 
by roosts, 17% to 26% (95% conﬁ  dence interval 17–27). 
In general, seroprevalence among females (n = 201; sero-
prevalence 26%) was greater than that among males (n = 
112; seroprevalence 19%). Although statistically insignif-
icant (χ2 = 2.38; p = 0.12), this difference was consistent 
across locations 1, 13, and 20. Only females were avail-
able from location 8. At all locations, Miniopterus bats 
shared caves with other species of insectivorous and fruit 
bats. However, no serologic activity against WCBV was 
detected in these other species. Of note, serum from fruit 
bats R. aegyptiacus that shared caves with Miniopterus 
bats neutralized LBV but not WCBV. Conversely, serum 
from Miniopterus bats neutralized WCBV but not LBV. 
This ﬁ  nding suggests that bats of different species, even 
those roosting in the same caves, do not readily expose 
each other to lyssaviruses.
Conclusions
We found WCBV-neutralizing antibodies in bats in 
Africa. Because limited serologic cross-reactivity between 
lyssaviruses and other rhabdoviruses has been demon-
strated (12), the WCBV seroprevalence we detected may 
have been caused by some other serologically related virus. 
However, to date no other agent that could cross-neutralize 
WCBV is known (7).
We cannot explain why 1 WCBV-neutralizing sample 
additionally neutralized DUVV. This ﬁ  nding could indi-
cate nonspeciﬁ  c virus inhibition, or it could be evidence of 
coexposure of the bat to several lyssaviruses. Our inabil-
ity to isolate viruses in this study is not surprising because 
lyssavirus prevalence in bat populations is usually low 
(<1%), even when seroprevalence is as high as 40%–70% 
(10,13,14). Indeed, the seroprevalence may reﬂ  ect past ex-
posures and peripheral virus activity rather than survival 
after clinical lyssavirus infection.
WCBV was ﬁ  rst isolated in 2002 in southeastern Eu-
rope from Miniopterus schreibersii (6) bats, and only 1 
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Figure 1. A) Map of Kenya showing locations of the bat collections, numbered in order of collection. B). Antibody titers to West Caucasian 
bat virus (WCBV) in Miniopterus bats from 4 of the locations. A modiﬁ  ed rapid ﬂ  uorescent focus inhibition test for WCBV-neutralizing 
antibodies was used. Bats with 50% end-point neutralizing titers >1 log10 were considered seropositive. Numbers of negative bats for each 
location are circled below the cutoff line.West Caucasian Bat Virus in Africa
isolate is available to date. Seroprevalence to this virus in 
African  Miniopterus bats is intriguing. Perhaps WCBV 
and similar viruses are speciﬁ  cally associated with Min-
iopterus bats and distributed quite broadly. Miniopterus 
bats are common in the tropics and subtropics of the Old 
World (15). They segregate into large colonies in caves. 
For example, in Kenya, Miniopterus colonies consisted of 
thousands of bats. Many of these caves are regularly vis-
ited by local residents and by tourists. Although no data 
exist for WCBV pathogenicity in humans, the absence of 
reliable vaccine protection against this virus and the abil-
ity of WCBV to cause fatal encephalitis in animal models 
(7) suggest the need for improved surveillance and public 
education to avoid exposure to bats.
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Figure 2. Colony of Miniopterus minor bats in cave.